View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
December 7, 2021updated 07 Jan 2022 8:21am

Chembio submits De Novo/510(k) Request to FDA for Covid-19 test system

The DPP SARS-CoV-2 Antigen test system detects SARS-CoV-2 antigens and provides results within 20 minutes.

Point-of-care diagnostic company Chembio Diagnostics has made a De Novo/510(k) Request submission to the US Food and Drug Administration (FDA) for its Covid-19 antigen test system.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The new dual path platform (DPP) SARS-CoV-2 Antigen test system is capable of detecting the virus antigens from a minimally invasive nasal swab sample and provides results within 20 minutes.

The results can be read using a DPP Micro Reader or DPP Micro Reader 2 optical analyser.

Chembio’s test has been developed using the company’s DPP technology, which has the ability to detect up to eight, distinct test results from the sample of a single patient.

The company received an award from the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to support the rapid DPP SARS-CoV-2 Antigen test system development.

The award also included funding to complete clinical studies as well as preparation for submitting a De Novo/510(k) for the new Covid-19 point-of-care system.

Chembio president and CEO Richard Eberly said: “The De Novo/510(k) Request for the DPP SARS-CoV-2 Antigen test system reflects our long-term strategy and commitment to deliver rapid, decentralised Covid testing solutions and broaden our portfolio of products in other disease categories that require rapid results for the US market.

“We would like to thank BARDA for their collaborative efforts in the development of both our Covid-19 tests and the respective regulatory submissions.

“We are hopeful for a straightforward review process with the FDA in order to offer healthcare providers additional testing solutions to support the evolving needs of the pandemic.”

The company’s DPP-based point-of-care tests that have secured regulatory approvals from the FDA include the DPP Ebola Antigen System and DPP Zika IgM System as well as the DPP HIV 1/2 Assay and DPP HIV-Syphilis System.

In 2018, Chembio Diagnostics received EUA from the US FDA to use its DPP Ebola Antigen System for the detection of the Ebola virus.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network